Compositions for pd-l1 inhibition and methods of use thereof
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsSally E. Dickinson, Georg Wondrak, Clara N. Curiel-Lewandrowski
Life of this patent
Estimating the term…
Abstract
One of three newly diagnosed cancers is skin cancer, making skin cancer the most common malignancy worldwide. Currently, no topically applied pharmacological interventions inhibit PD-L1 to protect against skin cancer and other solar radiation-induced skin damage. Thus, described herein are topical compositions comprising a small molecule antagonist of programmed death-ligand 1 (PD-L1), e.g., BSM-202, and methods of use thereof for skin protection.
Claims28
-2. (canceled)
A method of preventing and reversing damage caused by solar radiation of skin, comprising contacting the skin with a therapeutically effective amount of a topical composition comprising a small molecule antagonist of programmed death-ligand 1 (PD-L1), thereby protecting the skin from damage caused by solar radiation.
(canceled)
-11. (canceled)
-24. (canceled)
A method of protecting skin, comprising contacting the skin with a therapeutically effective amount of a topical composition comprising a small molecule antagonist of programmed death-ligand 1 (PD-L1), thereby protecting the skin.
(canceled)
-34. (canceled)
A method of preventing or treating skin cancer in a subject in need thereof, the method comprising topically administering a therapeutically effective amount of a composition comprising a small molecule antagonist of programmed death-ligand 1 (PD-L1).
(canceled)
-53. (canceled)
Dependencies are inferred from the claim text.